Compare Charles River Laboratories Intl. Inc (CRL) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VNET Group Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $284.74 (market cap $13.46B), while VNET Group Inc trades at $7.38 (market cap $2.14B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 6.3× VNET Group Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| CRL | VNET | |
|---|---|---|
Market Cap | $13.46B | $2.14B |
Sector | Health | Technology |
52-Week High | $282.00 | $14.03 |
52-Week Low | $145.57 | $6.29 |
Enterprise Value | $16.30B | $5.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
VNET trades at $7.565, up 1.14% today, with a neutral technical signal. The stock shows mixed fundamentals: revenue grew to $9.95B in 2025, but net losses deepened to -$256.77M. Recent news highlights strategic investor entry and AI-driven data center demand, yet earnings misses and a class action settlement pose concerns. Cash flow remains positive from financing, but profitability metrics like ROE at -43.21% signal challenges.
Outlook is cautious; analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and high debt-to-asset ratio of 50.18% heighten risk. Investors should weigh growth potential from AI expansion against execution and competitive pressures in China's data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
